Metastatic squamous cell carcinoma

disease

On this page

Summary

Metastatic squamous cell carcinoma (MONDO:0044907) is a cancer and 10 clinical trials. Top therapeutic interventions include tremelimumab, zanzalintinib, and irx-2. A subtype of squamous cell carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

Classification: Cancer
Clinical trials: 10

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	metastatic squamous cell carcinoma
Mondo ID	MONDO:0044907
NCIT	C4104
SNOMED CT	403906006
UMLS	C0334246
MedGen	90749
Is cancer (heuristic)	yes

Also known as: Metastatic squamous cell carcinoma

Disease family

This is a subtype of squamous cell carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › epithelial neoplasm › squamous cell neoplasm › squamous cell carcinoma › metastatic squamous cell carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 10.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	4
PHASE1/PHASE2	3
PHASE2	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03283605	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas
NCT04858269	PHASE2	ACTIVE_NOT_RECRUITING	First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
NCT04894370	PHASE2	RECRUITING	Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma
NCT07419464	PHASE2	RECRUITING	5-Fluorouracil Response and Optimization STudy (The FROST Trial)
NCT03847519	PHASE1/PHASE2	COMPLETED	Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer
NCT05783921	PHASE1/PHASE2	UNKNOWN	A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma
NCT06236425	PHASE1	ACTIVE_NOT_RECRUITING	TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
NCT06912087	PHASE1	RECRUITING	Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
NCT03381183	PHASE1	COMPLETED	IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma
NCT06357858	PHASE1	WITHDRAWN	ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
TREMELIMUMAB	4	1
ZANZALINTINIB	3	1
IRX-2	2	1

Drugs: Tremelimumab, Zanzalintinib